FDA Drug Recalls

Recalls / Class III

Class IIID-0309-2021

Product

Romidepsin Injecton, 27.5 mg/5.5 mL (5 mg/mL) Rx Only, 5.5 ml vial, Teva Pharmaceuticals USA, Inc. NDC 0703-4004-01

Affected lot / code info
Lot # 31328184C, exp. date 11/2021 Lot # 31327686C, exp. date 08/2021 Lot # 31327685C, exp. date 08/2021

Why it was recalled

Failed Impurity/Degradation Specifications: Out-of-specifications results observed for impurities during stability testing.

Recalling firm

Firm
Teva Pharmaceuticals USA
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
400 Interpace Pkwy, N/A, Parsippany, New Jersey 07054-1120

Distribution

Quantity
1,416 vials
Distribution pattern
Distributed Nationwide in the USA.

Timeline

Recall initiated
2021-03-04
FDA classified
2021-03-19
Posted by FDA
2021-03-24
Terminated
2022-05-19
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0309-2021. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class III recall: drug · FDA Drug Recalls